Avecho Biotechnology Ltd (AVE) - Net Assets

Latest as of December 2025: AU$1.56 Million AUD ≈ $1.10 Million USD

Based on the latest financial reports, Avecho Biotechnology Ltd (AVE) has net assets worth AU$1.56 Million AUD (≈ $1.10 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$7.11 Million ≈ $5.03 Million USD) and total liabilities (AU$5.55 Million ≈ $3.92 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AVE asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$1.56 Million
% of Total Assets	21.95%
Annual Growth Rate	-5.76%
5-Year Change	-65.62%
10-Year Change	-86.61%
Growth Volatility	100.12

Avecho Biotechnology Ltd - Net Assets Trend (1993–2025)

This chart illustrates how Avecho Biotechnology Ltd's net assets have evolved over time, based on quarterly financial data. Also explore AVE current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Avecho Biotechnology Ltd (1993–2025)

The table below shows the annual net assets of Avecho Biotechnology Ltd from 1993 to 2025. For live valuation and market cap data, see market value of Avecho Biotechnology Ltd.

Year	Net Assets	Change
2025-12-31	AU$1.56 Million ≈ $1.10 Million	-52.30%
2024-12-31	AU$3.27 Million ≈ $2.31 Million	-48.73%
2023-12-31	AU$6.38 Million ≈ $4.51 Million	+163.01%
2022-12-31	AU$2.42 Million ≈ $1.72 Million	-46.55%
2021-12-31	AU$4.54 Million ≈ $3.21 Million	+70.91%
2020-12-31	AU$2.65 Million ≈ $1.88 Million	-44.22%
2019-12-31	AU$4.76 Million ≈ $3.37 Million	+22.03%
2018-12-31	AU$3.90 Million ≈ $2.76 Million	-39.10%
2017-12-31	AU$6.40 Million ≈ $4.53 Million	-45.02%
2016-12-31	AU$11.65 Million ≈ $8.24 Million	-59.74%
2015-12-31	AU$28.93 Million ≈ $20.47 Million	-41.00%
2014-12-31	AU$49.03 Million ≈ $34.69 Million	+20.25%
2013-12-31	AU$40.77 Million ≈ $28.85 Million	-34.88%
2012-12-31	AU$62.61 Million ≈ $44.30 Million	-14.17%
2011-12-31	AU$72.95 Million ≈ $51.61 Million	+87.01%
2010-12-31	AU$39.01 Million ≈ $27.60 Million	-21.97%
2009-12-31	AU$49.99 Million ≈ $35.37 Million	-3.03%
2008-12-31	AU$51.55 Million ≈ $36.48 Million	-61.46%
2007-12-31	AU$133.76 Million ≈ $94.65 Million	-1.26%
2006-12-31	AU$135.47 Million ≈ $95.86 Million	+2.53%
2005-12-31	AU$132.14 Million ≈ $93.50 Million	+16.71%
2004-12-31	AU$113.22 Million ≈ $80.11 Million	+285.33%
2003-12-31	AU$29.38 Million ≈ $20.79 Million	+98.42%
2002-12-31	AU$14.81 Million ≈ $10.48 Million	-19.26%
2001-12-31	AU$18.34 Million ≈ $12.98 Million	-11.29%
2000-12-31	AU$20.67 Million ≈ $14.63 Million	+311.51%
1999-12-31	AU$5.02 Million ≈ $3.55 Million	+216.52%
1998-12-31	AU$1.59 Million ≈ $1.12 Million	-70.87%
1997-12-31	AU$5.45 Million ≈ $3.86 Million	-79.95%
1996-12-31	AU$27.18 Million ≈ $19.23 Million	-5.98%
1995-12-31	AU$28.90 Million ≈ $20.45 Million	+167.30%
1994-12-31	AU$10.81 Million ≈ $7.65 Million	+3.81%
1993-12-31	AU$10.42 Million ≈ $7.37 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Avecho Biotechnology Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 59233.5% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	AU$246.90 Million	15830.56%
Other Comprehensive Income	AU$653.82K	41.92%
Total Equity	AU$1.56 Million	100.00%

Avecho Biotechnology Ltd Competitors by Market Cap

The table below lists competitors of Avecho Biotechnology Ltd ranked by their market capitalization.

Company	Market Cap
TP ICAP Group PLC LSE:TCAP	$28.60 Million
Birman Wood and Hardware Ltd TA:BIRM	$28.61 Million
DIAMINES AND CHEMICALS ORD (BSE) NSE:DIAMINESQ	$28.62 Million
Kiattana Transport Public Company Limited BK:KIAT	$28.62 Million
Heartbeam Inc NASDAQ:BEAT	$28.59 Million
Ekso Bionics Holdings Inc NASDAQ:EKSO	$28.58 Million
GLORY HEALTH IND. HD-001 F:84R	$28.58 Million
Norse Atlantic ASA OL:NORSE	$28.57 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Avecho Biotechnology Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 3,269,738 to 1,559,650, a change of -1,710,088 (-52.3%).
Net loss of 4,416,623 reduced equity.
Share repurchases of 187,171 reduced equity.
New share issuances of 2,500,000 increased equity.
Other comprehensive income decreased equity by 27,402,164.
Other factors increased equity by 27,795,870.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$-4.42 Million	-283.18%
Share Repurchases	AU$187.17K	-12.0%
Share Issuances	AU$2.50 Million	+160.29%
Other Comprehensive Income	AU$-27.40 Million	-1756.94%
Other Changes	AU$27.80 Million	+1782.19%
Total Change	AU$-	-52.30%

Book Value vs Market Value Analysis

This analysis compares Avecho Biotechnology Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 23.04x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 0.03x to 23.04x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1993-12-31	AU$0.40	AU$0.01	x
1994-12-31	AU$0.39	AU$0.01	x
1995-12-31	AU$0.72	AU$0.01	x
1996-12-31	AU$0.88	AU$0.01	x
1997-12-31	AU$0.16	AU$0.01	x
1998-12-31	AU$0.05	AU$0.01	x
1999-12-31	AU$0.10	AU$0.01	x
2000-12-31	AU$0.25	AU$0.01	x
2001-12-31	AU$0.12	AU$0.01	x
2002-12-31	AU$0.10	AU$0.01	x
2003-12-31	AU$0.19	AU$0.01	x
2004-12-31	AU$0.63	AU$0.01	x
2005-12-31	AU$0.26	AU$0.01	x
2006-12-31	AU$0.24	AU$0.01	x
2007-12-31	AU$0.22	AU$0.01	x
2008-12-31	AU$0.08	AU$0.01	x
2009-12-31	AU$0.07	AU$0.01	x
2010-12-31	AU$0.05	AU$0.01	x
2011-12-31	AU$0.09	AU$0.01	x
2012-12-31	AU$0.06	AU$0.01	x
2013-12-31	AU$0.04	AU$0.01	x
2014-12-31	AU$0.04	AU$0.01	x
2015-12-31	AU$0.02	AU$0.01	x
2016-12-31	AU$0.01	AU$0.01	x
2017-12-31	AU$0.00	AU$0.01	x
2018-12-31	AU$0.00	AU$0.01	x
2019-12-31	AU$0.00	AU$0.01	x
2020-12-31	AU$0.00	AU$0.01	x
2021-12-31	AU$0.00	AU$0.01	x
2022-12-31	AU$0.00	AU$0.01	x
2023-12-31	AU$0.00	AU$0.01	x
2024-12-31	AU$0.00	AU$0.01	x
2025-12-31	AU$0.00	AU$0.01	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Avecho Biotechnology Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -283.18%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -356.82%
• Asset Turnover: 0.17x
• Equity Multiplier: 4.56x
Recent ROE (-283.18%) is below the historical average (-63.61%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1993	7.83%	0.00%	0.00x	1.14x	AU$-225.60K
1994	-3.15%	0.00%	0.00x	1.04x	AU$-1.42 Million
1995	60.97%	0.00%	0.00x	1.19x	AU$14.73 Million
1996	-11.39%	0.00%	0.00x	1.21x	AU$-5.81 Million
1997	-398.12%	0.00%	0.00x	1.01x	AU$-22.24 Million
1998	-243.30%	0.00%	0.00x	1.02x	AU$-4.02 Million
1999	10.02%	0.00%	0.00x	1.01x	AU$1.16K
2000	-5.68%	0.00%	0.00x	1.01x	AU$-3.24 Million
2001	-29.25%	0.00%	0.00x	1.00x	AU$-7.20 Million
2002	-29.37%	-3128.46%	0.01x	1.00x	AU$-5.83 Million
2003	-9.06%	-1108.23%	0.01x	1.00x	AU$-5.60 Million
2004	-2.78%	-1085.52%	0.00x	1.01x	AU$-14.47 Million
2005	-5.54%	-3979.89%	0.00x	1.29x	AU$-20.54 Million
2006	-4.52%	-444.16%	0.01x	1.28x	AU$-19.67 Million
2007	-6.61%	-557.63%	0.01x	1.28x	AU$-22.22 Million
2008	-176.92%	-5387.24%	0.02x	1.34x	AU$-96.36 Million
2009	-17.01%	-1268.81%	0.01x	1.35x	AU$-13.50 Million
2010	-28.91%	-241.95%	0.09x	1.38x	AU$-15.18 Million
2011	1.52%	43.96%	0.03x	1.05x	AU$-6.19 Million
2012	-17.66%	-722.55%	0.02x	1.02x	AU$-17.32 Million
2013	-31.08%	-921.00%	0.03x	1.05x	AU$-16.75 Million
2014	-18.22%	-435.22%	0.04x	1.04x	AU$-13.84 Million
2015	-69.55%	-918.72%	0.07x	1.06x	AU$-23.01 Million
2016	-148.66%	-1090.30%	0.12x	1.15x	AU$-18.48 Million
2017	-134.59%	-749.39%	0.14x	1.29x	AU$-9.26 Million
2018	-102.34%	-318.77%	0.26x	1.23x	AU$-4.38 Million
2019	17.86%	20.06%	0.80x	1.12x	AU$374.06K
2020	-99.27%	-685.08%	0.11x	1.26x	AU$-2.90 Million
2021	-75.30%	-430.44%	0.15x	1.16x	AU$-3.87 Million
2022	-96.58%	-207.44%	0.34x	1.38x	AU$-2.58 Million
2023	-53.89%	-725.79%	0.06x	1.15x	AU$-4.07 Million
2024	-95.48%	-275.55%	0.23x	1.53x	AU$-3.45 Million
2025	-283.18%	-356.82%	0.17x	4.56x	AU$-4.57 Million

Industry Comparison

This section compares Avecho Biotechnology Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $10,537,496
Average return on equity (ROE) among peers: -68.35%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Avecho Biotechnology Ltd (AVE)	AU$1.56 Million	7.83%	3.56x	$28.59 Million
Adalta Ltd (1AD)	$3.70 Million	-162.25%	0.87x	$6.50 Million
Algorae Pharmaceuticals Ltd (1AI)	$-1.33 Million	0.00%	0.00x	$20.04 Million
ACRUX Ltd (ACR)	$12.85 Million	-73.71%	0.44x	$3.20 Million
Actinogen Medical Ltd (ACW)	$21.74 Million	-43.69%	0.07x	$105.70 Million
Argenica Therapeutics Ltd (AGN)	$13.95 Million	-39.28%	0.17x	$15.45 Million
Arovella Therapeutics Ltd (ALA)	$11.03 Million	-40.87%	0.23x	$58.08 Million
Anatara Lifesciences Ltd (ANR)	$924.54K	-218.83%	0.54x	$1.57 Million
Alterity Therapeutics Ltd (ATH)	$20.73 Million	-6.40%	0.01x	$76.95 Million
Amplia Therapeutics Ltd (ATX)	$11.23 Million	-30.16%	0.02x	$50.82 Million

About Avecho Biotechnology Ltd

AU:AVE Australia Biotechnology

Market Cap

$28.59 Million

AU$40.41 Million AUD

Market Cap Rank

#23863 Global

#961 in Australia

Share Price

AU$0.01

Change (1 day)

-8.33%

52-Week Range

AU$0.00 - AU$0.01

All Time High

AU$0.04